ProKidney Corp (NASDAQ: PROK) on Tuesday, plunged -5.27% from the previous trading day, before settling in for the closing price of $0.88. Within the past 52 weeks, PROK’s price has moved between $0.86 and $4.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 3.70%. With a float of $93.03 million, this company’s outstanding shares have now reached $128.05 million.
The extent of productivity of a business whose workforce counts for 204 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of -241678.95%, and the pretax margin is -135193.42%.
ProKidney Corp (PROK) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ProKidney Corp is 28.18%, while institutional ownership is 43.98%. The most recent insider transaction that took place on Sep 19 ’24, was worth 41,030. In this transaction Chief Regulatory Officer of this company sold 16,412 shares at a rate of $2.50, taking the stock ownership to the 103,480 shares. Before that another transaction happened on Sep 19 ’24, when Company’s Officer proposed sale 16,412 for $2.39, making the entire transaction worth $39,225.
ProKidney Corp (PROK) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.70% per share during the next fiscal year.
ProKidney Corp (NASDAQ: PROK) Trading Performance Indicators
ProKidney Corp (PROK) is currently performing well based on its current performance indicators. A quick ratio of 10.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3036.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of ProKidney Corp (PROK)
The latest stats from [ProKidney Corp, PROK] show that its last 5-days average volume of 0.48 million was superior to 0.48 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 11.61%. Additionally, its Average True Range was 0.10.
During the past 100 days, ProKidney Corp’s (PROK) raw stochastic average was set at 0.33%, which indicates a significant decrease from 1.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.15% in the past 14 days, which was lower than the 92.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3097, while its 200-day Moving Average is $1.8638. Now, the first resistance to watch is $0.8816. This is followed by the second major resistance level at $0.9331. The third major resistance level sits at $0.9613. If the price goes on to break the first support level at $0.8019, it is likely to go to the next support level at $0.7737. Assuming the price breaks the second support level, the third support level stands at $0.7222.
ProKidney Corp (NASDAQ: PROK) Key Stats
Market capitalization of the company is 242.94 million based on 292,698K outstanding shares. Right now, sales total 80 K and income totals -61,190 K. The company made 80 K in profit during its latest quarter, and -21,280 K in sales during its previous quarter.
